Gastrointestinal manifestations and liver disorders in patients with COVID-19
DOI:
https://doi.org/10.5281/zenodo.10814332Keywords:
Cross-Sectional Studies, Gastrointestinal Tract, LiverAbstract
Background: SARS-CoV-2 infection began in Wuhan, China, in December 2019, where the first cases of pneumonia were described. The infection spread rapidly and was established as a pandemic by the World Health Organization (WHO) in February 2020. In Mexico, the first cases were in March 2020. Although the classic symptoms are respiratory, gastrointestinal symptoms have been described in 17%, as well as hepatic disorders associated with pneumonia.
Objective: To describe gastrointestinal manifestations and hepatic alterations in patients with COVID-19 from July 2020 to January 2021 in a tertiary-care hospital.
Material and methods: Clinical, cross-sectional, prolective, observational, analytical study, which included patients of 18 years or older hospitalized with COVID-19, confirmed by PCR for SARS-CoV-2.
Results: 84 patients were included, 65% male (55). Mean age was of 59 (± 13.3) years. Reported comorbidities were systemic arterial hypertension (51%), type 2 diabetes (38%), and obesity (26%). The predominant pattern was hepatocellular with elevation of AST (38) 45%, ALT (36)42%, GGT (30) 34% and FA (11) 13%. The prevalence of gastrointestinal symptoms was 71% (60/84), with diarrhea being the most frequent in 53% (4 bowel movements/day) and dysgeusia (36.9%). There were 12 patients (10.02%) who presented diarrhea as the initial symptom with respiratory complications 5-7 days later.
Conclusions: Gastrointestinal and hepatic manifestations occurred in 71% of the patients.
Downloads
References
Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, Zhang HY, Sun W, Wang Y. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Jun;92(6):577-583. doi: 10.1002/jmv.25757.
Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020 May 21;26(19):2323-2332. doi: 10.3748/wjg.v26.i19.2323.
Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med [Internet]. 2020 [consultado el 13 de marzo de 2024]; 288(2):192- 206. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32348588.
Musa S. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now? Arab J Gastroenterol [Internet]. 2020 [consultado el 13 de marzo de 2024];21(1):3-8. Disponible en: https://pubmed. ncbi.nlm.nih.gov/32253172.
Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol [Internet]. 2020 [consultado el 13 de marzo de 2024];5(7):667-78. doi: 10.1016/s2468-1253(20)30126-6.
Dhama K, Nainu F, Frediansyah A, et al. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. J Infect Public Health [Internet]. 2023 [consultado el 13 de marzo de 2024];16(1):4-14. doi: 10.1016/j.jiph.2022.11.024.
Alimohamadi Y, Sepandi M, Taghdir M, et al. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg [Internet]. 2020 [consultado el 13 de marzo de 2024];61(3). Disponible en: https://pubmed.ncbi.nlm.nih.gov/33150219.
Nagata N, Takeuchi T, Masuoka H, et al. Human gut Microbiota and its metabolites impact immune responses in COVID-19 and its complications. Gastroenterology [Internet]. 2023 [consultado el 13 de marzo de 2024];164(2):272–88. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36155191.
Buscarini E, Manfredi G, Brambilla G, et al. GI symptoms as early signs of COVID-19 in hospitalised Italian patients. Gut [Internet]. 2020 [consultado el 13 de marzo de 2024]; 69(8):1547-8. Disponible en: https://pubmed.ncbi.nlm.nih. gov/32409587.
Wong SH, Lui RNS, Sung JJY. Covid-19 and the digestive system. J Gastroenterol Hepatol [Internet]. 2020 [consultado el 13 de marzo de 2024];35(5):744-8. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/32215956.
Lippi G, Sanchis-Gomar F, Henry BM. COVID-19 and its long-term sequelae: what do we know in 2023? Pol Arch Med Wewn [Internet]. 2023 [consultado el 13 de marzo de 2024];133(4). Disponible en: https://pubmed.ncbi.nlm.nih. gov/36626183.
Garrido I, Lopes S, Simões MS, et al. Autoimmune hepatitis after COVID-19 vaccine – more than a coincidence. J Autoimmun [Internet]. 2021 [consultado el 13 de marzo de 2024];125 (102741):102741. Disponible en: https://pubmed.ncbi.nlm.nih. gov/34717185.
Wang H, Paulson KR, Pease SA, et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet [Internet]. 2022 [consultado el 13 de marzo de 2024];399(10334):1513-36. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35279232.
Comité de Evaluación Clínica Terapéutica. Manifestaciones Gastrointestinales del SARS-CoV-2. México: Academia Nacional de Medicina. Boletín de Información clínica Terapéutica; julio-agosto de 2020 [consultado el 12 de marzo de 2024]. Disponible en: https://www.anmm.org.mx/publicaciones/ boletin_clinico_terapeutico/2020/BCT-4-2020.pdf.
Schmulson M, Dávalos MF, Berumen J. Alerta: los síntomas gastrointestinales podrían ser una manifestación de la COVID-19. Rev Gastroenterol Mex [Internet]. 2020;85(3):282-7. doi: 10.1016/j.rgmx.2020.04.001.
Remes-Troche JM, Ramos-de la Medina A, Manríquez-Reyes M, et al. Initial gastrointestinal manifestations in patients with severe acute respiratory syndrome Coronavirus 2 infection in 112 patients from Veracruz in southeastern Mexico. Gastroenterology [Internet]. 2020;159(3):1179-81. doi: 10.1053/j. gastro.2020.05.055.
Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. Transl Res [Internet]. 2020 [consultado el 13 de marzo de 2024];226:57-69. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32827705.
Fernández-Rojas MA, Luna-Ruiz Esparza MA, Campos-Romero A, et al. Epidemiology of COVID-19 in Mexico: Symptomatic profiles and presymptomatic people. Int J Infect Dis [Internet]. 2021 [consultado el 13 de marzo de 2024];104:572- 9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33434668.
Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: Systematic review and meta-analysis. Gastroenterology [Internet]. 2020 [consultado el 13 de marzo de 2024];159(1):81-95. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/32251668/
Téllez L, Martín Mateos RM. Actualización en COVID-19 y enfermedad hepática. Gastroenterol Hepatol [Internet]. 2020 [consultado el 13 de marzo de 2024];43(8):472-80. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32727662.
Wong YJ, Tan M, Zheng Q, et al. A systematic review and meta-analysis of the COVID-19 associated liver injury. Ann Hepatol [Internet]. 2020 [consultado el 13 de marzo de 2024]; 19(6):627-34. Disponible en: https://pubmed.ncbi.nlm.nih. gov/32882393.
Marjot T, Webb GJ, Barritt AS IV, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol [Internet]. 2021 [consultado el 13 de marzo de 2024];18(5):348-64. Disponible en: https://pubmed.ncbi. nlm.nih.gov/33692570.
Kopel J, Perisetti A, Gajendran M, et al. Clinical insights into the gastrointestinal manifestations of COVID-19. Dig Dis Sci [Internet]. 2020 [consultado el 13 de marzo de 2024]; 65(7):1932-9. Disponible en: https://pubmed.ncbi.nlm.nih. gov/32447742.
Li P, Liu Y, Cheng Z, et al. COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management. Biomed Pharmacother [Internet]. 2022 [consultado el 13 de marzo de 2024];154(113568):113568. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36029543.
Hu WS, Jiang FY, Shu W, et al. Liver injury in COVID-19: A minireview. World J Gastroenterol [Internet]. 2022 [consultado el 13 de marzo de 2024];28(47):6716-31. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36620342.
Chen H, Chen Q. COVID-19 pandemic: Insights into interactions between SARS-CoV-2 infection and MAFLD. Int J Biol Sci [Internet]. 2022 [consultado el 13 de marzo de 2024];18 (12):4756–67. Disponible en: https://pubmed.ncbi.nlm.nih. gov/35874945.
Wu Y, Pan Y, Su K, et al. Elder and booster vaccination associates with decreased risk of serious clinical outcomes in comparison of Omicron and Delta variant: A meta-analysis of SARS-CoV-2 infection. Front Microbiol [Internet]. 2023 [consultado el 13 de marzo de 2024];14. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/37125157.
Meo SA, Meo AS, Al-Jassir FF, et al. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci [Internet]. 2021 [consultado el 13 de marzo de 2024];25(24). Disponible en: https://pubmed.ncbi.nlm.nih.gov/34982465.
Tokuyama K, Kitamura T, Maruyama K, et al. High number of seizures and unconsciousness in patients with SARS-CoV-2 omicron variants: a retrospective study. Front Pediatr [Internet]. 2023 [consultado el 13 de marzo de 2024];11. Disponible en: https://pubmed.ncbi.nlm.nih.gov/38034823.
Li J, Zhang Q, Xu C, et al. Differences in clinical characteristics and liver injury between patients diagnosed with the Omicron subvariant BA.5.2 and the prototype of SARS-CoV-2: a single center retrospective study. BMC Gastroenterol [Internet]. 2023 [consultado el 13 de marzo de 2024];23(1). Disponible en: https://pubmed.ncbi.nlm.nih.gov/37553605.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Revista Médica del Instituto Mexicano del Seguro Social
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.
